PURPOSE For survivors of childhood cancer treated with doxorubicin, dexrazoxane is
cardioprotective for at least 5 years. However, longer-term data are lacking. METHODS …

Despite major advances in cancer treatment, anthracycline-related cardiotoxicity remains a
major cause of morbidity and mortality in survivors of childhood cancer. Promising areas of …

Anthracyclines are highly effective chemotherapeutic agents, used for a wide variety of
malignancies. Cardiotoxicity is a well‑recognized side effect of anthracycline therapy that …

The cardiotoxicity of anthracyclines has been studied extensively, yet many uncertainties
persist. A vast number of reports address not only the clinical features of anthracycline …

Cardiotoxicity is a feared side effect that may limit the clinical use of anthracyclines. It may
indeed affect the quality of life and survival of patients with cancer, regardless of oncological …

The fact that anthracyclines are cardiotoxic seriously narrows their therapeutic index in
cancer therapy. The cardiotoxic risk increases with the cumulative dose and may lead to …

Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast
cancer among many others. However, anthracycline treatment can be cardiotoxic. Although …

Over the last 40 years, great progress has been made in treating childhood and adult
cancers. However, this progress has come at an unforeseen cost, in the form of emerging …

Chemotherapy-induced cardiotoxicity is a major cause of morbidity and mortality in cancer
survivors. It might manifest as arrhythmia, hypertension, myocardial ischemia …

Despite the known cardiotoxic effects of doxorubicin and other anthracyclines, no evidence-
based guidelines exist for the surveillance and prevention of chemotherapy-induced …